Canada • TSX Venture Exchange • TSX-V:TELO • CA87975M2085
The current stock price of TELO.CA is 0.045 CAD. In the past month the price decreased by -10%. In the past year, price decreased by -62.5%.
Over the last trailing twelve months TELO.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 19.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -446.15% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Telo Genomics Corp. is a molecular diagnostics company, which engages in the development of telomere analysis platforms in the industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. The company quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.
TELO GENOMICS CORP
Mars Centre, 101 College St Suite 200
TORONTO ONTARIO M5G 1L7 CA
CEO: Sherif Louis
Employees: 0
Phone: 14166738487
Telo Genomics Corp. is a molecular diagnostics company, which engages in the development of telomere analysis platforms in the industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. The company quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.
The current stock price of TELO.CA is 0.045 CAD.
TELO.CA does not pay a dividend.
TELO.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
TELO GENOMICS CORP (TELO.CA) currently has 0 employees.
TELO GENOMICS CORP (TELO.CA) will report earnings on 2026-02-24.
You can find the ownership structure of TELO GENOMICS CORP (TELO.CA) on the Ownership tab.